Management of Mycoplasma Pneumonia-Associated Autoimmune Hemolytic Anemia

Clinical Presentation and Initial Management

The American College of Physicians recommends stopping the antibiotic immediately and initiating high-dose corticosteroids (1-2 mg/kg/day prednisone or methylprednisolone) as first-line therapy for patients with Mycoplasma pneumoniae-induced autoimmune hemolytic anemia (AIHA) 1, 2
For Grade 3 autoimmune hemolytic anemia (Hgb <8.0 g/dL), guidelines recommend prednisone 1-2 mg/kg/day (oral or IV depending on severity), with corticosteroids being first-line therapy for warm autoimmune hemolytic anemia and demonstrating efficacy in Mycoplasma-associated cases 1, 2

The National Comprehensive Cancer Network recommends a direct antiglobulin test (DAT/Coombs test) should be positive for IgG and/or C3d to confirm diagnosis 1
Transfuse packed red blood cells only if hemoglobin drops to life-threatening levels (<7-8 g/dL) or if symptomatic, and provide folic acid supplementation (1 mg daily) to support erythropoiesis 1

Consider adding IVIG (0.4-1 g/kg/day for 3-5 days) if no improvement within 72 hours of high-dose corticosteroids, hemoglobin continues to drop despite steroid therapy, or patient develops life-threatening complications 1, 3
Consider rituximab (375 mg/m² weekly × 4 doses) only if patient fails both corticosteroids and IVIG, hemolysis persists beyond 2 weeks of appropriate therapy, or patient requires repeated transfusions 2, 3

If continued antimicrobial therapy is needed for pneumonia, switch to a macrolide (azithromycin or clarithromycin) or a respiratory fluoroquinolone, as these are less commonly associated with DIIHA 1, 4, 5
Most Mycoplasma pneumoniae cases improve with 7-10 days of appropriate antibiotic therapy 4, 5

Do not delay corticosteroids while waiting for serologic confirmation—clinical presentation is sufficient to initiate therapy, and avoid excessive transfusions, as they can worsen hemolysis in some cases 1
Do not use aminoglycosides if restarting antibiotics, as they have no role in Mycoplasma treatment and carry nephrotoxicity risk in the setting of hemoglobinuria 6